As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, demonstrating a +1.72% change from the ...

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.

Pacific Biosciences of California faces steep stock decline and financial challenges. Click here to see why PACB stock is a ...

Pacific Biosciences offers advanced long-read sequencing, simplifying genome assembly and providing higher taxonomic resolution in specific research niches. While earnings were a beat, shrinking ...

A research team has identified two novel genetic mechanisms for disease resistance in wheat, offering promising strategies to ...

June 26, 2025, is the 25th anniversary of the White House announcement of the first sequencing of the human genome, and July 28, 2025, marks the 30th anniversary of the publication of the first ...

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: ...

Volta Labs, a genomics applications company, today announced the launch of its Library Prep App for Oxford Nanopore LSK114 on ...

PacBio said it is solidifying and expanding its distribution agreement with a local company, with plans to grow the footprint of its hi-fi long-read sequencers among both clinical and research labs.